Study: Psoriasis Drug May Help Treat Crohn's Disease
The results of a new study indicate a drug used to treat psoriasis shows positive results in decreasing the effects of Crohn's disease, according to a news release.
The study was conducted by researchers at University of California San Diego School of Medicine and appeared in the New England Journal of Medicine.
A clinical trial conducted by the researchers showed ustekinumab (Stelara), an antibody proven to treat psoriasis, increased clinical response and remission in patients suffering from moderate-to-severe Crohn's disease. The randomized trial involved 526 patients conducted in 12 countries.
"Our biggest challenge in treating patients with Crohn's disease is managing patients whose bodies are resistant to tumor necrosis factor inhibitors such as Remicade, Humira and Cimzia," said William Sanborn, MD, principal investigator and chief of the division of gastroenterology at the UC San Diego School of Medicine, in the release. "Ustekinumab blocks two proteins that cause inflammation, interleukin 12 and 23. This finding is a significant first step towards a new treatment option for these patients."
Related Articles on Gastroenterology:
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Patient identification complexity & why the industry is still trying to get it right: 5 considerations
- The Center for Musculoskeletal Disorders installs Mazor system in ambulatory outpatient setting: 4 things to know
- 5 financial thoughts for mid-career physicians
- ASA, ePreop partner on quality reporting software: 5 notes
- RIVANNA partners with Vertec Scientific to market new anesthesia device: 3 notes